Effect of protein binding on the pharmacological activity of highly bound antibiotics.
During antibiotic drug development, media are frequently spiked with either serum/plasma or protein supplements to evaluate the effect of protein binding. Usually, previously reported serum or plasma protein binding values are applied in the analysis. The aim of this study was to evaluate this approach by experimentally measuring free, unbound concentrations for antibiotics with reportedly high protein binding and their corresponding antimicrobial activities in media containing commonly used protein supplements. Free, unbound ceftriaxone and ertapenem concentrations were determined in bacterial growth medium with and without bovine/human serum albumin, as well as adult bovine serum and human plasma using in vitro microdialysis. The corresponding antimicrobial activity was determined in MIC and time-kill curve experiments using Escherichia coli ATCC 25922 and Streptococcus pneumoniae ATCC 6303 as test strains. A semimechanistic maximum effect model was simultaneously fitted to the data and respective EC(50) (concentration at half-maximum effect) values compared. Protein binding differed significantly for ceftriaxone (P < 0.05) between human plasma (76.8 +/- 11.0%) and commercially available bovine (20.2 +/- 8.3%) or human serum albumin (56.9 +/- 16.6%). Similar results were obtained for ertapenem (human plasma, 73.8 +/- 11.6%; bovine serum albumin, 12.4 +/- 4.8%; human serum albumin, 17.8 +/- 11.5%). The MICs and EC(50)s of both strains were significantly increased (P < 0.05) for ceftriaxone when comparing human and bovine serum albumin, whereas the EC(50)s were not significantly different for ertapenem. Free, unbound antibiotic concentrations differed substantially between plasma and protein supplements and correlated well with antimicrobial efficacy. Therefore, free, active concentrations should be measured in the test system instead of correcting for literature protein binding values.
Schmidt
Stephan
S
Department of Pharmaceutics, University of Florida, College of Pharmacy, Gainesville, Florida 32610-0494, USA.
Röck
Katharina
K
Sahre
Martina
M
Burkhardt
Olaf
O
Brunner
Martin
M
Lobmeyer
Maximilian T
MT
Derendorf
Hartmut
H
D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology*; D001798:Blood Proteins / Q000378:metabolism*; D002417:Cattle; D002443:Ceftriaxone / Q000378:metabolism / Q000494:pharmacology; D055808:Drug Discovery; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000187:drug effects; D047090:beta-Lactams / Q000378:metabolism / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D012709:Serum Albumin; D047090:beta-Lactams; D012710:Serum Albumin, Bovine; D002443:Ceftriaxone; D000077727:Ertapenem
Science. 2004 Sep 10;305(5690):1622-5
15308767
J Antimicrob Chemother. 2006 Sep;58(3):632-6
16840426
J Antimicrob Chemother. 2004 Jul;54(1):259-62
15150172
J Antimicrob Chemother. 2007 Jun;59(6):1185-9
17412725
Clin Chem. 1985 Jan;31(1):60-4
3917383
Farmaco Sci. 1977 Apr;32(4):303-10
862884
Antimicrob Agents Chemother. 1990 Jun;34(6):1257-8
2393287
J Antimicrob Chemother. 1983 Mar;11(3):233-8
6841305
Clin Pharmacokinet. 2001;40(9):685-94
11605716
J Antimicrob Chemother. 2004 Nov;54(5):876-80
15472003
J Antimicrob Chemother. 1998 Jul;42(1):95-8
9700535
Expert Opin Drug Discov. 2007 Jun;2(6):849-60
23489002
J Antimicrob Chemother. 2002 Oct;50(4):525-32
12356797
Clin Pharmacokinet. 1989 Oct;17(4):223-35
2686882
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77
14742182
J Chemother. 1998 Feb;10(1):29-34
9531073
J Antimicrob Chemother. 2007 Dec;60(6):1388-90
17951265
J Antimicrob Chemother. 2008 Mar;61(3):561-7
18216178
Chemotherapy. 1981;27 Suppl 1:42-6
7249794
Antimicrob Agents Chemother. 1991 Dec;35(12):2505-8
1667253
Pharm Res. 1990 Oct;7(10):1077-81
2281040
Clin Pharmacol Ther. 1981 May;29(5):650-7
7053242
J Vet Pharmacol Ther. 1989 Sep;12(3):253-60
2810474
Drugs. 1981;22 Suppl 1:52-9
6456892
J Pharm Biomed Anal. 2004 Sep 3;35(5):1293-9
15336375
J Infect Dis. 1981 Apr;143(4):609-16
7240802
J Antimicrob Chemother. 2005 May;55(5):601-7
15772142
J Pharm Sci. 1997 Jan;86(1):52-6
9002459
Expert Rev Anti Infect Ther. 2005 Jun;3(3):361-73
15954853
Antimicrob Agents Chemother. 2007 Jan;51(1):128-36
17060524
J Hosp Infect. 1990 Apr;15 Suppl A:23-34
1971641
J Antimicrob Chemother. 2007 Jul;60(1):156-8
17483149
Antimicrob Agents Chemother. 1989 Jan;33(1):35-40
2496656
Int J Antimicrob Agents. 2007 Mar;29(3):263-70
17194570
Xenobiotica. 1987 Oct;17(10):1139-45
3424863
Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69
3542337
Int J Pharm. 2006 Mar 27;311(1-2):108-12
16431044
Antimicrob Agents Chemother. 2004 Sep;48(9):3419-24
15328106
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 18;830(2):218-23
16290251